Evidence map›Paper›PMID 32734234›Full record

ArticleKidney medicine

Time to Initiation of Antihypertensive Therapy After Onset of Elevated Blood Pressure in Patients With Primary Proteinuric Kidney Disease.

Donald J Weaver, Anne Waldo, Gia J Oh, Elaine S Kamil, Matthew Elliott, Sharon Adler, Anne Pesenson, Meg M Modes, Patrick Gipson, Richard A Lafayette and 6 more

Abstract read
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Longitudinal analysis of blood pressure and lipids in childhood nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2024 · on this map
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Donald J WeaverDivision of Pediatric Nephrology, Levine Children's Hospital at Atrium Health, Charlotte, NC.
Anne WaldoDivision of Nephrology, Department of Pediatrics & Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI.
Gia J OhDivision of Nephrology, Department of Pediatrics, Stanford University, Stanford, CA.
Elaine S KamilCedars-Sinai Medical Center, Los Angeles, CA.
Matthew ElliottMetrolina Nephrology Associates, Charlotte, NC.
Sharon AdlerLos Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA.
Anne PesensonThe Polyclinic, Seattle, WA.
Meg M ModesPatient Advocate, Livonia, MI.
Patrick GipsonDivision of Nephrology, Department of Pediatrics & Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI.
Richard A LafayetteDivision of Nephrology and Hypertension, Stanford University, Stanford, CA.
David T SelewskiDivision of Nephrology, Department of Pediatrics & Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI.
Samara E AttallaDivision of Nephrology, Department of Pediatrics & Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI.
Richard EikstadtDivision of Nephrology, Department of Pediatrics & Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI.
Jonathan P TroostDivision of Nephrology, Department of Pediatrics & Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI.
Debbie S GipsonDivision of Nephrology, Department of Pediatrics & Communicable Diseases, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI.
Susan F MassengillDivision of Pediatric Nephrology, Levine Children's Hospital at Atrium Health, Charlotte, NC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE &

objectiveThe objective of the study was to estimate the prevalence of hypertension in patients with proteinuric kidney disease and evaluate blood pressure (BP) control. STUDY

designRetrospective cohort study. SETTING &

participantsData from adults and children with proteinuric kidney disease enrolled in the multicenter Kidney Research Network Registry were used for this study. EXPOSURE: Proteinuric kidney disease. OUTCOMES: Hypertension and BP control. ANALYTICAL APPROACH: Patients with white-coat hypertension were excluded. Patients were censored at end-stage kidney disease onset. Patients were defined as hypertensive either by hypertension diagnosis code, having 2 or more encounters with elevated BPs, or treatment with antihypertensive therapy excluding renin-angiotensin-aldosterone system blockade. Elevated BP was defined as greater than 95th percentile for children and >140/90 mm Hg in adults. Sustained BP control was defined as 2 or more consecutive encounters with BPs lower than 95th percentile for children and <140/90 mm Hg for adults. Kaplan-Meier and Cox proportional hazards analyses were used to evaluate the time to initiation of antihypertensive therapy.

results842 patients, 69% adults and 31% children, with a total observation period of 6,722 patient-years were included in the analysis. 644 (76%) had hypertension during observation. There was no difference in the prevalence of hypertension between children and adults (74% vs 78%; LIMITATIONS: Differing BP control goals that may lead to overestimation of the controlled patient population.

conclusionsHypertension affects most patients with proteinuric kidney disease regardless of age. Time to BP control exceeded 1 year in 50% of patients with hypertension and 22% did not demonstrate control. This study highlights the need to address hypertension early and completely in disease management of patients with proteinuric kidney disease.

Indexed as

Chronic kidney diseaseelevated blood pressurehypertensionproteinuria

Identifiers

PMID32734234
PMCPMC7380443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.